Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-09-26Clinical Trial Update: Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines [Phase 2]
Phase 2 trial evaluating carfilzomib plus elotuzumab and dexamethasone for relapsed multiple myeloma after 1-3 prior treatments has complete…
-
CLINICAL_TRIALS trial_result · 2023-09-21Clinical Trial Update: Allo HSCT Using RIC for Hematological Diseases [Phase 2]
Phase 2 trial evaluating allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for various hematologic dise…
-
CLINICAL_TRIALS trial_result · 2023-09-11Clinical Trial Update: Stem Cell Translpantation in Multiple Myeloma [Phase 2]
Phase 2 clinical trial update on stem cell transplantation for multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2023-09-08Clinical Trial Update: Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients [Phase 2]
Phase 2 clinical trial update evaluating carfilzomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple myeloma patients.
-
CLINICAL_TRIALS trial_result · 2023-09-06Clinical Trial Update: Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment [Phase 1]
A Phase 1 trial evaluating the combination of ixazomib and pevonedistat in patients with recurrent or refractory multiple myeloma has comple…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-09-06Clinical Trial Update: CURATE.AI Optimized Modulation for Multiple Myeloma [Phase 2, Phase 3]
Clinical trial update for CURATE.AI optimized modulation in multiple myeloma across Phase 2 and Phase 3.
-
CLINICAL_TRIALS trial_result · 2023-08-28Clinical Trial Update: Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment [Phase 2]
Phase 2 trial evaluating daratumumab in relapsed/refractory multiple myeloma with renal impairment has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-08-28Clinical Trial Update: Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody. [Phase 1, Phase 2]
Clinical trial update for a humanized CAR-T targeting BCMA (ARI0002h) in relapsed/refractory multiple myeloma, undergoing Phase 1/Phase 2 ev…
-
CLINICAL_TRIALS trial_result · 2023-08-22Clinical Trial Update: A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy [Phase 3]
Phase 3 trial evaluating venetoclax in combination with bortezomib and dexamethasone for relapsed/refractory multiple myeloma has completed …
-
CLINICAL_TRIALS trial_result · 2023-08-22Clinical Trial Update: Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) [Phase 2]
Phase 2 trial evaluating Pembrolizumab plus Lenalidomide after autologous stem cell transplant in high-risk multiple myeloma was terminated;…
-
CLINICAL_TRIALS trial_result · 2023-08-22Clinical Trial Update: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating AO-176 as monotherapy and in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma ha…
-
CLINICAL_TRIALS trial_result · 2023-08-21Clinical Trial Update: Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma [Phase 2]
Phase 2 trial of nivolumab, ixazomib, cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma was terminated with result…
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) [Phase 2]
A Phase 2 MATCH-subprotocol trial is evaluating trametinib for cancers with GNAQ or GNA11 mutations; the study is active/not recruiting and …
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide [Phase 2]
Phase 2 clinical trial evaluating daratumumab with low-dose dexamethasone and cyclophosphamide, with or without pomalidomide, in relapsed or…
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma [Phase 2]
A Phase 2 trial evaluates lenalidomide plus melphalan in patients with previously untreated multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 clinical trial update for AT9283 in relapsed or refractory multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2023-08-03Clinical Trial Update: Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06) [Phase 2]
Phase 2 clinical trial evaluating a triplet regimen (MLN9708, Lenalidomide, Dexamethasone) for newly diagnosed multiple myeloma; study compl…
-
CLINICAL_TRIALS trial_result · 2023-08-02Clinical Trial Update: Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) [Phase 2]
Phase 2 MATCH subprotocol study evaluating trametinib for cancers with NF1 genetic changes has posted results; the trial is currently not re…
-
CLINICAL_TRIALS trial_result · 2023-07-24Clinical Trial Update: A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders [Phase 2]
Phase 2 clinical trial update on desensitization for allergic reactions to treatments used for blood disorders, completed.
-
CLINICAL_TRIALS trial_result · 2023-07-10Clinical Trial Update: Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma [Phase 2]
Phase 2 trial evaluating daratumumab with bortezomib and dexamethasone in newly diagnosed transplant-ineligible multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2023-07-03Clinical Trial Update: Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD) [Phase 1, Phase 2]
A Phase 1/2 trial evaluating a combination of carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma has compl…
-
CLINICAL_TRIALS trial_result · 2023-07-03Clinical Trial Update: Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients [Phase 1, Phase 2]
Phase 1/2 trial evaluating a combination of carfilzomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple myeloma; the study …
-
CLINICAL_TRIALS trial_result · 2023-06-29Clinical Trial Update: Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning [Phase 2]
Phase 2 trial update on allogeneic transplantation using timed sequential busulfan and fludarabine conditioning for various hematologic mali…
-
CLINICAL_TRIALS trial_result · 2023-06-29Clinical Trial Update: Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients [Phase 3]
Phase 3 trial comparing Velcade, Melphalan, Prednisone and Thalidomide versus Velcade, Melphalan, Prednisone in patients with multiple myelo…
-
CLINICAL_TRIALS trial_result · 2023-06-29Clinical Trial Update: Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients [Phase 2]
Phase 2 clinical trial update evaluating Revlimid (lenalidomide) and prednisone followed by Revlimid, melphalan, and prednisone in patients …